ESMO20: KEYNOTE 590 will change practice for patients with oesophagus Cancer

Ken Kato | ESMO 2020 | Onkologi /hematologi | September 24, 2020

Speaker: Ken Kato

The KEYNOTE 590 trial examined first-line chemotherapy, with or without pembrolizumab, in patients with squamous cell carcinoma of the oesophagus, adenocarcinoma of the oesophagus, or Siewert type 1 gastro-oesophageal junction adenocarcinoma. In this MEDtalk Ken Kato, MD. PhD, National Cancer Center Hospital, Tokyo, presents the results of the KEYNOTE 590 study.

PhD Ken Kato, Chief of The Department of Head, Neck and Esophageal Medical Oncology, National Cancer Center, Tokyo, Japan